Skip to main content
Clinical Trials/NCT06751030
NCT06751030
Recruiting
N/A

Community, Home-based Education, Screening Services (CHESS) Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria

Emory University3 sites in 1 country1,500 target enrollmentDecember 3, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV
Sponsor
Emory University
Enrollment
1500
Locations
3
Primary Endpoint
Program Reach
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims:

  • Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population.
  • Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity.
  • Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.

Detailed Description

Despite the increased risk of cervical cancer (CC) among women living with HIV (WLWH), access to CC screening in Nigeria remains limited. While advances in prevention programs and antiretroviral therapy have reduced other AIDS-associated malignancies, CC risk in WLWH persists. This study aims to leverage Nigeria's existing HIV treatment infrastructure to integrate home-based CC (HCC) screening for WLWH. The approach involves adapting the MoMent (MOther MENTor) peer-based HIV support program to include HCC screening and evaluating its implementation and sustainability using the Consolidated Framework for Implementation Research (CFIR) and RE-AIM frameworks. The study has three key aims: * Adapting the MoMent program to promote home-based HPV screening and follow-up treatment through stakeholder deliberation. * Implementing and assessing the program's reach, effectiveness, adoption, and fidelity with a sample of 1,500 WLWH. * Conducting a post-implementation evaluation to identify barriers and enablers for program maintenance and scalability. Stakeholder input, including perspectives from WLWH, peer counselors, clinical managers, and policymakers, will guide the program's design and execution. By integrating stakeholder insights and addressing systemic challenges, the study aims to advance CC control in Nigeria and provide a scalable model for implementing cancer control strategies for people living with HIV in low- and middle-income countries globally.

Registry
clinicaltrials.gov
Start Date
December 3, 2024
End Date
June 1, 2026
Last Updated
8 months ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lisa Flowers

Professor

Emory University

Eligibility Criteria

Inclusion Criteria

  • Patients must be able to perform vaginal self-collection as well as give informed consent

Exclusion Criteria

  • Male gender
  • Age \<25 or \>50
  • Unknown or negative HIV status
  • Pregnancy
  • Hysterectomy
  • Inability to give informed consent Inability/refusal to perform vaginal self-collection

Outcomes

Primary Outcomes

Program Reach

Time Frame: Baseline, Month 6, Month 18

Reach evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or reoccurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load.

Adoption of the program

Time Frame: Baseline, Month 6, Month 18

Adoption will be measured through the proportions of MMs who complete training and WLWH who return self-collected (SC) samples

Effectiveness of the Program

Time Frame: Baseline, Month 6, Month 18

Effectiveness evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or recurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load.

Fidelity of the program

Time Frame: Baseline, Month 6, Month 18

Will be measured by peer leaders' monitoring of practices, as well as measuring system barriers and added MoMent program costs per completed home screening

Study Sites (3)

Loading locations...

Similar Trials